Treatment for Type 2 Diabetes Mellitus

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Johns Hopkins Pediatric Diabetes Center, Baltimore, MD
Type 2 Diabetes Mellitus+4 More
Eligibility
< 65
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to determine if use of a nonmydriatic fundus camera using autonomous artificial intelligence software at the point of care increases the proportion of underserved youth with diabetes screened for diabetic retinopathy.

Eligible Conditions

  • Type 2 Diabetes Mellitus
  • Diabetes Related Cystic Fibrosis
  • Type 1 Diabetes Mellitus

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 2 years

2 years
Percentage of agreement in interpretation of retinal images
Proportion screened for diabetic retinopathy

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

500 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years
Closest Location: Johns Hopkins Pediatric Diabetes Center · Baltimore, MD
Photo of Baltimore 1Photo of Baltimore 2Photo of Baltimore 3
2022First Recorded Clinical Trial
3 TrialsResearching Type 2 Diabetes Mellitus
2 CompletedClinical Trials

Who is running the clinical trial?

National Eye Institute (NEI)NIH
514 Previous Clinical Trials
1,073,575 Total Patients Enrolled
2 Trials studying Type 2 Diabetes Mellitus
2,308 Patients Enrolled for Type 2 Diabetes Mellitus
Johns Hopkins UniversityLead Sponsor
2,033 Previous Clinical Trials
30,781,875 Total Patients Enrolled
11 Trials studying Type 2 Diabetes Mellitus
1,072 Patients Enrolled for Type 2 Diabetes Mellitus
Risa M Wolf, MDPrincipal InvestigatorJohns Hopkins University
1 Previous Clinical Trials
41 Total Patients Enrolled
1 Trials studying Type 2 Diabetes Mellitus
41 Patients Enrolled for Type 2 Diabetes Mellitus

Eligibility Criteria

Age < 65 · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have Type 2 diabetes.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References